最新公告列表 《2025年前三季度权益分派实施公告》 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 截至2025年11月28日收盘，美好医疗（301363）报收于21.23元，较前一交易日上涨0.66%，最新总市值 为120.77亿元。该股当日开盘21.09元，最高21.35元，最低21.01元，成交额达6742.93万元，换手率为 0.85%。 近日，美好医疗发布2025年前三季度权益分派实施公告。公告显示，公司2025年前三季度权益分派方案 已获通过，以总股本568,871,180股剔除回购股份1,132,048股后的567,739,132股为基数，向全体股东每10 股派发现金红利0.80元（含税），合计派发45,419,130.56元。本次不送红股，不进行资本公积转增股 本。股权登记日为2025年12月5日，除权除息日为2025年12月8日。现金红利由中国结算深圳分公司代 派，部分股东由公司自行派发。 ...

证券日报网讯 11月28日晚间，美好医疗发布公告称，本公司2025年前三季度权益分派方案为：以公司 现有总股本568，871，180股剔除回购专用证券账户中1，132，048股后的567，739，132股为基数，向 全体股东每10股派0.800000元人民币现金（含税）。股权登记日为2025年12月5日，除权除息日为2025 年12月8日。 （文章来源：证券日报） ...

1 证券代码：301363 证券简称：美好医疗 公告编号：2025-074 深圳市美好创亿医疗科技股份有限公司 2025年前三季度权益分派实施公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、截至本公告披露日，深圳市美好创亿医疗科技股份有限公司（以下简称 "公司"或"本公司"）回购专用证券账户持有公司股份 1,132,048 股。根据《上 市公司股份回购规则》及《深圳证券交易所上市公司自律监管指引第 9 号——回 购股份》等相关规定，该部分已回购的股份不享有参与本次利润分配的权利。因 此，公司本次权益分派以现有总股本 568,871,180 股剔除回购专用证券账户持有 的 1,132,048 股后的 567,739,132 股为基数，向全体股东每 10 股派发现金红利人 民币 0.80 元（含税），合计派发现金红利人民币 45,419,130.56 元（含税）。本 次不送红股，不进行资本公积转增股本。 2、本次权益分派实施后，按公司总股本（含回购股份）折算的每 10 股现金 分红（含税）=本次实际现金分红总额÷公司总股本（含回购股份）×10 ...

Core Viewpoint - The stock of Meihao Medical (301363) has shown fluctuations in trading volume and capital flow, with a slight increase in share price on November 27, 2025, despite net outflows from major and retail investors [1][2]. Financial Performance - For the first three quarters of 2025, Meihao Medical reported a main revenue of 1.194 billion yuan, a year-on-year increase of 3.28%, while the net profit attributable to shareholders was 208 million yuan, a decrease of 19.25% [3]. - In Q3 2025, the company achieved a single-quarter main revenue of 462 million yuan, up 2.56% year-on-year, and a net profit of 93.90 million yuan, an increase of 5.89% year-on-year [3]. - The company's gross profit margin stands at 39.34%, with a net profit margin of 17.43% [3]. Market Position - Meihao Medical's total market capitalization is 11.997 billion yuan, which is higher than the industry average of 11.026 billion yuan, ranking 25th out of 124 in the medical device industry [3]. - The company has a price-to-earnings ratio (P/E) of 43.22, which is lower than the industry average of 56.75, ranking 48th out of 124 [3]. - The return on equity (ROE) is 5.79%, significantly higher than the industry average of 0.15%, ranking 43rd out of 124 [3]. Investor Sentiment - Over the past 90 days, 14 institutions have rated the stock, with 12 buy ratings and 2 hold ratings, indicating positive sentiment among analysts [4]. - The average target price set by institutions for the stock is 25.2 yuan [4].

Core Viewpoint - The stock of Meihai Medical (301363) has shown a slight decline in price, with significant net outflows from major funds, indicating potential investor concerns about the company's performance and market conditions [1][2]. Group 1: Stock Performance - As of November 26, 2025, Meihai Medical's stock closed at 20.89 yuan, down 0.29% with a turnover rate of 0.78% and a trading volume of 29,300 hands, resulting in a transaction amount of 61.61 million yuan [1]. - Over the past five days, the stock has experienced fluctuations, with a notable drop on November 21, 2025, where it fell by 3.79% [2]. Group 2: Fund Flow Analysis - On November 26, 2025, the net outflow of major funds was 479.83 million yuan, accounting for 7.79% of the total transaction amount, while retail investors saw a net inflow of 106.12 million yuan, representing 1.72% of the total [1][2]. - The recent trend shows that major funds have been withdrawing, with a cumulative net outflow over the past five days [2]. Group 3: Financial Metrics and Industry Comparison - Meihai Medical's total market capitalization is 11.884 billion yuan, with a net asset value of 3.702 billion yuan and a net profit of 208 million yuan [3]. - The company's price-to-earnings ratio (P/E) stands at 42.81, which is lower than the industry average of 54.59, while its price-to-book ratio (P/B) is 3.21, also below the industry average of 3.86 [3]. - The gross margin for Meihai Medical is 39.34%, significantly lower than the industry average of 51.22%, indicating potential challenges in cost management [3]. Group 4: Recent Institutional Ratings - In the last 90 days, 14 institutions have rated Meihai Medical, with 12 buy ratings and 2 hold ratings, suggesting a generally positive outlook among analysts [4]. - The average target price set by institutions over the past 90 days is 25.2 yuan, indicating potential upside from the current trading price [4].

Core Insights - The stock of Meihao Medical (301363) closed at 20.95 yuan on November 25, 2025, with a slight increase of 0.58% and a trading volume of 34,400 hands, resulting in a transaction amount of 72.4574 million yuan [1] Fund Flow Analysis - On November 25, 2025, the net outflow of main funds was 2.3287 million yuan, accounting for 3.21% of the total transaction amount, while retail investors saw a net inflow of 465,400 yuan, representing 0.64% of the total [1][2] - Over the past five days, the stock experienced fluctuating fund flows, with significant net outflows from main funds on November 24 and November 21, totaling 4.2916 million yuan and 5.3390 million yuan respectively [2] Company Performance Metrics - Meihao Medical's total market capitalization is 11.918 billion yuan, with a net asset value of 3.702 billion yuan and a net profit of 208 million yuan [3] - The company's price-to-earnings ratio (P/E) stands at 42.93, while the price-to-book ratio (P/B) is 3.22, indicating a relatively high valuation compared to the industry averages [3] - The gross margin is reported at 39.34%, which is lower than the industry average of 51.22%, while the net profit margin is 17.43%, significantly higher than the industry average of 9.57% [3] Recent Institutional Ratings - In the last 90 days, 14 institutions have rated the stock, with 12 buy ratings and 2 hold ratings, indicating a positive outlook from analysts [4] - The average target price set by institutions over the past 90 days is 25.2 yuan, suggesting potential upside from the current trading price [4]

Core Viewpoint - The stock of Meihao Medical (301363) has shown fluctuations in trading performance, with a recent closing price of 20.83 yuan, reflecting a 2.51% increase on November 24, 2025, amidst varying capital flows [1][2]. Financial Performance - For the first three quarters of 2025, Meihao Medical reported a main business revenue of 1.194 billion yuan, a year-on-year increase of 3.28%, while the net profit attributable to shareholders was 208 million yuan, a decline of 19.25% [3]. - In Q3 2025, the company achieved a single-quarter main business revenue of 462 million yuan, up 2.56% year-on-year, and a net profit of 93.9 million yuan, an increase of 5.89% year-on-year [3]. Capital Flow Analysis - On November 24, 2025, the net outflow of main funds was 4.29 million yuan, accounting for 4.82% of the total transaction amount, while retail investors saw a net inflow of 9.61 million yuan, representing 10.78% of the total transaction amount [1][2]. - Over the past five days, the stock has experienced varying capital flows, with significant net outflows from main and speculative funds on several days [2]. Industry Comparison - Meihao Medical's total market value stands at 11.85 billion yuan, slightly above the industry average of 10.978 billion yuan, ranking 25th out of 124 in the medical device sector [3]. - The company's price-to-earnings ratio (P/E) is 42.69, which is lower than the industry average of 55.96, ranking 50th in the industry [3]. Analyst Ratings - In the last 90 days, 14 institutions have rated the stock, with 12 buy ratings and 2 hold ratings, indicating a generally positive outlook [4].

Core Insights - The roundtable discussion at the "2025 Huaxia Health Industry Development and Rehabilitation Service Conference" focused on the commercialization of brain-computer interfaces (BCIs) in mental rehabilitation treatment, exploring the transition from individual cases to clinical applications [1] Group 1: Industry Perspectives - Experts and executives from various companies, including Airdoc, Meihao Medical, Ruiyi Biotechnology, and Yaoxin Medical, shared insights on the commercial prospects of BCIs [1] - The discussion emphasized the potential of BCIs to create a trillion-dollar market, raising questions about who will finance this commercialization [1]

Core Viewpoint - The stock of Meihao Medical (301363) has experienced a decline, with a closing price of 20.32 yuan on November 21, 2025, down 3.79% from the previous day, indicating a negative trend in recent trading activity [1]. Financial Performance - For the first three quarters of 2025, Meihao Medical reported a main business revenue of 1.194 billion yuan, a year-on-year increase of 3.28% [3]. - The net profit attributable to shareholders was 208 million yuan, a year-on-year decrease of 19.25% [3]. - The third quarter of 2025 saw a single-quarter main business revenue of 462 million yuan, up 2.56% year-on-year, and a net profit of 93.90 million yuan, up 5.89% year-on-year [3]. - The company’s gross profit margin stands at 39.34%, which is lower than the industry average of 51.22% [3]. Market Position and Valuation - Meihao Medical has a total market capitalization of 11.559 billion yuan, ranking 26th in the medical device industry [3]. - The company’s price-to-earnings ratio (P/E) is 41.64, which is lower than the industry average of 54.54, ranking 49th [3]. - The price-to-book ratio (P/B) is 3.12, compared to the industry average of 3.77, ranking 78th [3]. - The return on equity (ROE) is 5.79%, significantly higher than the industry average of 0.15%, ranking 43rd [3]. Recent Trading Activity - On November 21, 2025, the net outflow of main funds was 5.339 million yuan, accounting for 6.37% of the total transaction amount [1][2]. - Over the past five days, the stock has seen fluctuations in fund flows, with notable net inflows and outflows from different investor categories [2]. - The average target price set by 14 institutions over the past 90 days is 25.2 yuan, with 12 buy ratings and 2 hold ratings [4].

Core Viewpoint - The stock of Meihao Medical (301363) has shown a slight increase in price, with significant net inflows from major funds, indicating potential investor interest despite some outflows from retail investors [1][2]. Financial Performance - As of November 20, 2025, Meihao Medical's stock closed at 21.12 yuan, up 0.62%, with a trading volume of 30,300 lots and a total transaction value of 63.8864 million yuan [1]. - In the third quarter of 2025, the company reported a main business revenue of 462 million yuan, a year-on-year increase of 2.56%, and a net profit attributable to shareholders of 93.9002 million yuan, a year-on-year increase of 5.89% [3]. - For the first three quarters of 2025, the company's main revenue was 1.194 billion yuan, a year-on-year increase of 3.28%, while the net profit decreased by 19.25% to 208 million yuan [3]. Market Position and Valuation - Meihao Medical's total market capitalization is 12.015 billion yuan, with a net asset value of 3.702 billion yuan and a net profit of 208 million yuan [3]. - The company's price-to-earnings ratio (P/E) is 43.28, which is lower than the industry average of 55.37, indicating a relatively favorable valuation [3]. - The gross profit margin stands at 39.34%, significantly lower than the industry average of 51.22%, while the net profit margin is 17.43%, higher than the industry average of 9.57% [3]. Institutional Ratings - Over the past 90 days, 14 institutions have rated the stock, with 12 buy ratings and 2 hold ratings, suggesting a positive outlook from analysts [4]. - The average target price set by institutions for the stock is 25.2 yuan, indicating potential upside from the current trading price [4].